Literature DB >> 32799654

Differences between exhausted CD8+ T cells in hepatocellular carcinoma patients with and without uremia.

Chen Xiaohong1,2,3,4,5, Zou Jianzhou1,2,3,4,5, Shen Bo1,2,3,4,5, Lv Wenlv1,2,3,4,5, Cao Xuesen1,2,3,4,5, Xiang Fangfang1,2,3,4,5.   

Abstract

The purpose of this study was to explore the differences between exhausted CD8+ T cells in hepatocellular carcinoma (HCC) patients with and without uremia. We enrolled 45 uremic patients who were recently diagnosed with HCC into the HCC + uremia cohort and similar patients with HCC but without uremia into the HCC-only cohort. Lymphocytes were obtained from the two cohorts, and exhausted CD8+ T cells, comprising PD-1+CD8+, TIM-3+CD8+, and LAG-3+CD8+ T cells, were sorted and expanded in vitro. After expansion, the proportions of PD-1+CD8+, TIM-3+CD8+, and LAG-3+CD8+ T cells were significantly higher in the HCC-only cohort than in the HCC + uremia cohort. CD8+ T cells expressing PD-1, TIM-3, or LAG-3 showed increased tumor reactivity and release of interferon-γ in vitro; however, these cells demonstrated weaker anti-tumor activity in HCC + uremia patients than in HCC-only patients. Among the expanded lymphocytes, only the decreased proportion of PD-1+CD8+ T cells significantly correlated with the HCC + uremia cohort (odds ratio of 2.731, p = 0.009). We concluded that peripheral CD8+ T cells expressing PD-1, TIM-3, or LAG-3 from the HCC + uremia cohort were dysfunctional in vitro. Among these populations, PD-1+CD8+ T cells were most evident in HCC patients with uremia.

Entities:  

Keywords:  LAG-3; PD-1; TIM-3; carcinome hépatocellulaire; hepatocellular carcinoma; uremia; urémie

Year:  2020        PMID: 32799654     DOI: 10.1139/cjpp-2019-0641

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  1 in total

1.  Study on Nursing Effect of Psychological Intervention on Uremic Hemodialysis Patients.

Authors:  Yan Chen; Jie Ding; Chunqing Li; Ting Wu; Qingya Li; Rujing Chen; Jingfen Zhou
Journal:  Comput Math Methods Med       Date:  2022-07-13       Impact factor: 2.809

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.